Answers are grounded in this paper and cite their sources.
Although immune checkpoint inhibitors (ICIs) have transformed breast cancer treatment, predicting durable clinical benefit remains challenging. Current biomarkers, primarily derived from tumor tissue or peripheral blood, do not directly capture the adaptive immune response at its site of initiation. Tumor-draining lymph nodes (TDLNs) are not passive conduits for metastasis but dynamic immunological hubs where anti-tumor T cell priming and immune evasion converge. In this review, we critically examine the nascent intersection of TDLN immunobiology, high-resolution multi-omics, and artificial intelligence (AI) to evaluate TDLN-derived features as candidate next-generation biomarkers for immunotherapy. We synthesize the complex cellular and molecular architecture of the breast cancer TDLN, including T cell exhaustion, B cell-mediated immunity, and stromal crosstalk, before evaluating the state-of-the-art single-cell and spatial technologies capable of decoding this microenvironment. We assess the application of AI and foundation models in this domain, identifying a major methodological gap: while AI frameworks are increasingly mature for primary tumors, their application to TDLNs remains unvalidated and limited by a severe scarcity of annotated multi-omics datasets. Furthermore, we address pivotal translational considerations, including the immunological implications of axillary surgery in the ICI era. We emphasize that no TDLN-derived biomarker has yet undergone prospective validation as a predictive biomarker for immunotherapy in breast cancer, and that retrospective analyses of trial specimens must account for the timing of tissue acquisition relative to systemic therapy. Finally, we chart immediate research priorities, including establishing TDLN reference atlases and developing clinically feasible specimen collection pathways for biomarker validation. This review provides a conceptual framework and translational roadmap to assess whether TDLN-derived features can complement existing tumor-centric metrics in guiding immunotherapy decisions.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: